Topic: Astrazeneca Group
An FDA advisory committee's strong vote in favor of AstraZeneca's (AZN) blood-thinner Brilinta was tempered by long-held concerns over the failure of the drug's pivotal trial to show a survival benefit in the US population when compared to Plavix (Event - Brilinta ...
ADELPHI, Maryland (Reuters) - U.S. advisers backed a potential blockbuster blood thinner from AstraZeneca on Wednesday, a victory for a company seeking new drugs to offset expiring patents on some of its best-selling medicines.Members of a Food and Drug Administration panel voted ...
In this study, 48% fewer deaths reported among heart bypass patients taking ticagrelor (BRILINTA(TM)/BRILIQUE(TM)) as compared to clopidogrel. AZN) today announced results of a new analysis of the PLATO (A Study of PLATelet Inhibition and Patient Outcomes) study which showed there were ...
AstraZeneca today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome (ACS). The ...
AZN) today announced the results of the phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) at the annual American Heart Association (AHA) Scientific Sessions in Orlando, FL,(1,2) with ONSET/OFFSET study results being simultaneously published in the medical journal Circulation. The ONSET/OFFSET ...
AZN) today announced results of a PLATO sub-analysis in the most serious type of Acute Coronary Syndrome (ACS) patients, those with ST Segment Elevation Myocardial Infarction (STEMI). In this setting, ST segment elevation indicates total obstruction of a coronary artery which warrants ...
AstraZeneca remains on track to submit BRILINTA to regulatory authorities in the fourth quarter of this year.. The bleeding definitions used within the PLATO trial were an evolution from the CURE bleeding definitions and were developed by the PLATO Executive Committee as ...
In patients with acute coronary syndromes, ticagrelor reduces the rate of death, heart attack, and stroke better than clopidogrel, without increasing the rate of overall major bleeding, according to a study published online Aug. 30 in the New England Journal of Medicine ...
AstraZeneca today announced results from the phase III head to head trial, PLATO (A Study of Platelet Inhibition and Patient Outcomes), which demonstrate that ticagrelor (BRILINTAT) has achieved greater efficacy in the primary endpoint, reduction of cardiovascular events (CV death, MI, stroke) ...
BARCELONA (Reuters) - AstraZeneca's new pill Brilinta for preventing heart attacks works better than Plavix, the world's second biggest selling drug, without increasing the amount of life-threatening bleeding, researchers said on Sunday.The positive clinical trial result should ensure the blood thinner wins ...
From Around the Web
Video Gallery
-
Penny Stoker - AstraZeneca Pharmaceuticals LP
Penny Stoker, vice presdient, global hr services at AstraZeneca Pharmaceuticals ...2009-04-07 -
AstraZeneca - Tanuj
Tanuj is a physician who combined his health information and ...2011-11-28 -
AstraZeneca - Melissa
Melissa is a Senior Scientist who is part of a ...2011-11-28
